MissionIR Articles
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Conversion of Additional $7.24M of Debt into Equity
Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) this morning announced the conversion of an additional $7.24 million of debt into equity, bringing the total amount of debt that has converted into equity over…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Boosts Drug Development Process through Acquisition of PreEMT™ Platform
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently acquired the PreEMT™ platform to develop a unique manufacturing method and improve the quality of a key protein-based drug being developed. A recent article discussing the…
-
Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs
Biologics offer novel ways of treating degenerative diseases like Alzheimer’s Biologics are one of the fastest-growing drug categories PreEMT™ technology improves quality, reduces cost of biologic manufacture When we think of drugs, an image of…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Increase in Revenue, Debt Conversion in Q1 2018
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently announced financial results for the first quarter ended March 31, 2018. Among other highlights, the company reported first quarter revenue growth and debenture conversion. An article…
-
Revenue Growth, Debt Conversion Boost Pressure BioSciences’ (PBIO) Outlook at Close of First Quarter
High-pressure lab equipment maker reports ninth consecutive quarter of revenue growth (Y/Y) About 92 percent of debenture debt converted to preferred stock, with aim of uplisting to national stock exchange Patented technologies continue to drive…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Q1 Financial Results, Provides Business Update; Schedules Earnings Call
Global life sciences company Pressure BioSciences (OTCQB: PBIO) today announced financial results for the first quarter ended March 31, 2018. Among other highlights, Pressure BioSciences reported total revenue of $610,774 for the first quarter of…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement Related to Recently Acquired PreEMT™ Platform
Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) today announced that it has signed an agreement with an international biopharmaceutical company to assess the potential of PBIO’s recently acquired PreEMT™ platform to develop a…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO to Host Webinar on May 2
Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) this morning announced that Richard T. Schumacher, the company’s president and CEO, will be hosting a webinar update and live Q&A session for investors today at…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Sees 2018 as Year of Growth for BaroFold, Ultra Shear Technology Programs
Pressure BioSciences (OTCQB: PBIO) recently announced newly-issued patents in Ultra Shear Technology (“UST”) that address broad markets for stable, water-soluble nanoemulsions, including cannabinoids. An article further discussing the company reads: “With the BaroFold acquisition and…
-
Pressure BioSciences Inc.’s (PBIO) New Products and Enhanced Sales Capabilities Drive Plans for Banner 2018
Record product sales growth reported for fourth quarter and full year 2017 Company has over 300 of its ultra-high pressure instruments in research labs worldwide 2017 revenue exceeded $2.2 million with just one field sales…
-
MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Sets Teleconference to Discuss FY2017 Results
Global life sciences company Pressure BioSciences, Inc. (OTCQB: PBIO) this morning announced that it plans to host a teleconference to discuss its fourth quarter and fiscal year 2017 financial results and to provide a business…
-
MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Novel Technology Enables Industrial Level Production of Nanoemulsions
Amid the growing demand for nanoemulsions, Pressure BioSciences (OTCQB: PBIO) boasts a patented novel technique called Ultra Shear Technology (“UST”). UST process produces highly stable, clean and cost-effective nanoemulsions. An article further discussing the company’s…
-
Pressure BioSciences’ (PBIO) Patented Tech Enhances Nanoemulsion Bioavailability and Extends Product Shelf Life
Patented UST process produces highly stable, clean and cost-effective nanoemulsions Technology can be applied across many industries, including pharmaceutical, food, nutraceutical, industrial lubricant, paint and cosmetic sectors UST technology aligns with consumer demand for chemical-…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement to Create Unique Analytical System Using Patented Pressure Cycling Technology
Pressure BioSciences (OTCQB: PBIO) recently entered a global co-marketing and distribution agreement with ISS, Inc. to create an advanced high pressure optical spectroscopy system utilizing PBIO’s patented pressure cycling technology (“PCT”). An article further discussing…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Technology Could Provide Ideal Drug Delivery of Cannabinoids
Pressure BioSciences’ (OTCQB: PBIO) patented technology may provide the ideal transport for CBD and other cannabinoids. The company’s novel Ultra Shear Technology (“UST) has the capacity to develop water-soluble nanoemulsions that can be employed to…
-
Pressure BioSciences Inc. (PBIO) Agreement with ISS, Inc. Shows Potential to Enhance Drug Discovery and Development
The two companies entered co-marketing and distribution agreement to be implemented worldwide Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development The joint…
-
Pressure BioSciences Inc. (PBIO) Just Might Have the Ideal Drug Delivery Technology for Cannabinoids
The tide of cannabis legalization continues to rise Medical cannabis market on pace to hit $56 billion in seven years Company’s proprietary technology improves the bioavailability of cannabinoids With the passage of laws permitting medicinal…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Co-Marketing, Distribution Agreement with ISS, Inc.
Pressure BioSciences (OTCQB: PBIO) this morning said it has entered a two-year, global co-marketing and distribution agreement with ISS, Inc. The companies intend to combine the ISS high pressure optical cell with Pressure BioSciences’ automated…
-
MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO Discusses Recent Corporate Milestones in Webinar Update
Pressure BioSciences Inc. (OTCQB: PBIO) CEO Richard T. Schumacher earlier this week hosted a webinar update and live Q&A session for prospective investors. During the presentation, Schumacher detailed each of PBIO’s three distinct working groups,…
-
MissionIRNewsBreaks – Pressure BioSciences, Inc.’s (PBIO) Entry into Biopharmaceutical Industry Focus of Zacks Small Cap Research Article
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the global life sciences industry, was recently the focus of a publication by Zacks Small Cap Research titled “PBIO: Enters…
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option